Fairfield, Connecticut, United States
IMS Health (NYSE: RX), the world's leading provider of market intelligence to the pharmaceutical and healthcare industries, announced expanded capabilities and expertise to support clients' growing need for comprehensive, clinically rich insights into the global oncology market. Supported by the company's strong foundation of information assets, advanced analytics, and consulting capabilities, IMS's team of oncology experts is helping clients make critical, evidence-based decisions--from the pre-clinical stage through the entire product lifecycle. IMS's strategic support to pharmaceutical and biotech clients in oncology includes market assessment, forecasting and competitive intelligence, pricing, reimbursement, and health economics and outcomes research.
Oncology, the second largest and fastest growing therapeutic class in the world, is expected to become the leading class by 2010 with annual sales doubling to $66 billion. With nine new oncology products slated to launch in 2007 and more than 90 products in Phase III clinical trials or pre-approval stage, growth in this market shows no sign of slowing.
"IMS has been working aggressively to broaden our oncology information assets and consulting expertise to address our clients' compelling need to better understand this growing and dynamic market," said Gilles Pajot, executive vice president, IMS. "Today, we have the clinical depth, commercial breadth, and global reach in oncology that can guide and drive our clients' commercial decisions in ways no one else can."
Following the acquisition of several companies that include the Centre for Outcomes Research, Health Outcomes Research Europe, and Strategic Analysis Inc. to expand the range of its oncology and health economics expertise, IMS announced its alliance with IntrinsiQ Research, the premiere provider of U.S. oncology information. The alliance provides an exclusive license to incorporate IntrinsiQ's U.S.-based anonymized patient-level oncology information into IMS's multi-country oncology offering, Oncology Analyzer(R). With the integration of U.S. information, clients have a complete view of cancer care into seven major countries--covering 85 percent of the world oncology market--through one of the largest commercially available resources for insights on chemotherapy treatments. These strategic moves have enabled IMS to offer clients unparalleled data assets and expertise in managing their oncology franchises.
IMS has completed more than 140 engagements related to oncology over the past 18 months, and has provided pricing and market access strategic advisory consulting for nine of the top 10 oncology products introduced over the past two years.
Today, IMS has more than 60 professionals with deep oncology experience in market access, pricing and reimbursement, product and portfolio development, competitive intelligence, and forecasting. The global oncology team includes MDs, PharmDs, and PhDs in virology, biochemistry, molecular biology, gene therapy and other disciplines. IMS also has built substantial expertise in health economics and outcomes research to support the industry's growing need for evidence of the clinical value, safety and benefit of oncology medicines.
"All stakeholders in oncology face critical challenges in addressing the issues that are surfacing due to increasing availability of more effective, innovative drugs," said Mary Beth Lawrence, global head of Launch and Brand Management, IMS. "This innovation is fueling a demand for therapies that is increasingly incompatible with today's available healthcare budgets and resources, and the debate on what represents value to justify incremental expense is heating up. IMS has become a valued partner in helping demonstrate the clinical and economic benefits of these new medicines."
IMS's robust global oncology information, combined with its other core data assets, offers clients unmatched insights into patient treatment history as well as oncology product uptake--what products are most often prescribed in various markets, their effectiveness in treating certain types of cancer, and the length of those treatments. The integration of this information is increasingly important to clients in order to gain a complete understanding of this highly complex therapeutic class.
Said Pajot, "We are building on an already strong foundation of capabilities and expertise, helping pharmaceutical and biotech clients support their strategic decisions at the headquarters level, and execute more effective operational plans locally. IMS brings a level of credibility and knowledge of this market to clients that is world-class--enabling us to become their partner of choice as they launch and manage their products in an evolving market."
For more information visit IMS Health's oncology web site at: http://www.imshealth.com/oncology
About IMS
Operating in more than 100 countries, IMS Health is the world's leading provider of market intelligence to the pharmaceutical and healthcare industries. With $1.8 billion in 2005 revenue and more than 50 years of industry experience, IMS offers leading-edge business intelligence products and services that are integral to clients' day-to-day operations, including portfolio optimization capabilities; launch and brand management solutions; sales force effectiveness innovations; managed care and over-the-counter offerings; and consulting and services solutions that improve ROI and the delivery of quality healthcare worldwide. Additional information is available at http://www.imshealth.com.
CONTACT: IMS Communications Barbara Henderson 610-260-6639 bphenderson@us.imshealth.com
CONTACT: IMS Communications Barbara Henderson 610-260-6639 bphenderson@us.imshealth.com , ,
Source: Business Wire (Business Wire India)